Answers are grounded in this paper and cite their sources.
Scientific review demonstrates top-down proteomics for profiling intact proteoforms in human diseases, highlighting its critical role in identifying candidate biomarkers.
The proteome is a dynamic landscape of proteoforms arising from genetic mutations, alternative splicing, and post‐translational modifications (PTMs), which collectively drive biological function and disease phenotypes. Mass spectrometry (MS)‐based proteomics has emerged as an essential technique for elucidating this molecular complexity. Although bottom‐up proteomics enables deep protein identification and quantification through peptide‐level analysis, it disrupts molecular connectivity and introduces a peptide‐to‐protein inference problem, which is suboptimal for proteoform analysis. Top‐down proteomics (TDP) offers a complementary approach by analyzing intact proteins, preserving molecular connectivity, and enabling direct characterization and quantification of proteoforms. This capability is increasingly vital for understanding heterogeneous human diseases. Here, we review the evolving role of TDP in biomedical research, highlighting studies that revealed proteoform‐level alterations, identified candidate biomarkers, and advanced our understanding of the roles of proteoforms in human diseases.
No takes yet. Share an insight, caveat, or question.
Rogers et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: